CheckMan Stock Market Overview

Here are four top-performing liquid stocks, Abercrombie & Fitch (ANF), Semrush Holdings (SEMR), Crexendo (CXDO) and QuickLogic Corporation (QUIK), which investors can add to their portfolio to augment returns.

Northrop Grumman (NOC) came out with quarterly earnings of $6.32 per share, beating the Zacks Consensus Estimate of $5.83 per share. This compares to earnings of $5.50 per share a year ago.

Sonic Automotive (SAH) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.33 per share a year ago.

FMC Technologies (FTI) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to break-even earnings per share a year ago.

MarineMax (HZO) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $1.23 per share a year ago.

U.S. stock futures fell in premarket trading on Thursday after Meta spooked investors with its AI spending plans, raising concerns about what awaits when Microsoft and Google report after the bell.

Monster Beverage Corp. was downgraded two notches to sell from buy at Truist Securities because the energy drink maker is no longer seen as a high-growth business, analysts said.

Darling Ingredients (DAR) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $1.16 per share a year ago.

LONG ISLAND CITY, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Steven Madden, Ltd. (NASDAQ: SHOO), a leading designer and marketer of fashion-forward footwear, accessories and apparel, today announced that the Company plans to release its first quarter 2024 earnings results on Wednesday, May 1, 2024. Management will host a conference call to review the results at 8:30 a.m. Eastern Time.

AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study.